Patienterne, der hovedsagelig var mænd mellem 35 og 44 år, blev behandlet i mindst ét år med enten Baraclude eller lamivudin.
Patients were mostly male, aged between 35 and 44 years of age, and they received at least one year of treatment with either Baraclude or lamivudine.